HC Wainwright Predicts AnaptysBio FY2030 Earnings

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at HC Wainwright issued their FY2030 earnings per share (EPS) estimates for shares of AnaptysBio in a research report issued to clients and investors on Wednesday, March 4th. HC Wainwright analyst E. Bodnar expects that the biotechnology company will post earnings of $7.67 per share for the year. HC Wainwright has a “Buy” rating and a $66.00 price objective on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share.

AnaptysBio (NASDAQ:ANAB) last released its quarterly earnings data on Monday, March 9th. The biotechnology company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.89 by $0.69. AnaptysBio had a negative net margin of 5.64% and a negative return on equity of 1,101.24%. The company had revenue of $108.25 million during the quarter, compared to analyst estimates of $87.09 million.

A number of other analysts also recently weighed in on the stock. Wedbush reissued an “outperform” rating and set a $50.00 price target on shares of AnaptysBio in a research report on Monday, November 24th. Truist Financial lifted their price target on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research note on Monday, November 10th. Guggenheim restated a “buy” rating on shares of AnaptysBio in a research note on Thursday, December 18th. Wall Street Zen lowered AnaptysBio from a “strong-buy” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of AnaptysBio in a report on Wednesday, January 21st. Nine investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $71.89.

AnaptysBio Price Performance

Shares of ANAB stock opened at $57.28 on Thursday. AnaptysBio has a 12 month low of $15.32 and a 12 month high of $63.47. The firm has a market capitalization of $1.65 billion, a P/E ratio of -110.15 and a beta of 0.32. The company’s fifty day moving average price is $50.17 and its two-hundred day moving average price is $38.78.

Institutional Trading of AnaptysBio

Large investors have recently added to or reduced their stakes in the business. Caitong International Asset Management Co. Ltd grew its position in AnaptysBio by 940.8% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,530 shares of the biotechnology company’s stock worth $74,000 after buying an additional 1,383 shares during the last quarter. Invesco Ltd. boosted its stake in shares of AnaptysBio by 192.6% during the 4th quarter. Invesco Ltd. now owns 124,006 shares of the biotechnology company’s stock worth $6,012,000 after acquiring an additional 81,625 shares in the last quarter. Mackenzie Financial Corp acquired a new position in shares of AnaptysBio in the 4th quarter worth $1,166,000. XTX Topco Ltd grew its holdings in shares of AnaptysBio by 113.3% in the 4th quarter. XTX Topco Ltd now owns 38,637 shares of the biotechnology company’s stock worth $1,873,000 after acquiring an additional 20,526 shares during the last quarter. Finally, nVerses Capital LLC acquired a new stake in shares of AnaptysBio during the fourth quarter worth $215,000.

Insider Transactions at AnaptysBio

In related news, insider Eric J. Loumeau sold 12,500 shares of AnaptysBio stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $44.86, for a total transaction of $560,750.00. Following the transaction, the insider directly owned 9,088 shares of the company’s stock, valued at $407,687.68. The trade was a 57.90% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Dennis Mulroy sold 15,725 shares of the company’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total transaction of $705,266.25. Following the completion of the sale, the chief financial officer directly owned 9,401 shares of the company’s stock, valued at $421,634.85. The trade was a 62.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 156,280 shares of company stock worth $7,254,939. Corporate insiders own 33.50% of the company’s stock.

AnaptysBio announced that its Board of Directors has approved a stock repurchase plan on Friday, November 21st that authorizes the company to buyback $100.00 million in shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its shares through open market purchases. Shares buyback plans are usually an indication that the company’s leadership believes its stock is undervalued.

Trending Headlines about AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Stifel Nicolaus raised its price target to $85 and reiterated a Buy rating, signaling substantial upside vs. current levels. Stifel Nicolaus price-target raise
• Positive Sentiment: Barclays raised its target to $79 and moved to an Overweight rating, another institutional endorsement that supports upside expectations. Barclays price-target raise
• Positive Sentiment: H.C. Wainwright boosted its target to $66 and kept a Buy rating; the firm’s analyst also published a long‑range FY2030 EPS projection (~$7.67), which is far above current consensus and implies strong optionality from AnaptysBio’s assets. H.C. Wainwright price-target raise HC Wainwright FY2030 note
• Neutral Sentiment: AnaptysBio announced a spin‑off of its biopharma portfolio — a strategic move that can unlock value long term but often creates short‑term uncertainty until details (timing, tax treatment, assets) are disclosed. Spin-off announcement
• Neutral Sentiment: Short‑interest reports show a reported “large increase” but list zero shares and NaN changes — data appears inconsistent and likely not a meaningful signal. (Treat short‑interest data as noisy/uncertain until clarified.)
• Negative Sentiment: Despite positive analyst action, intraday selling and higher-than-average volume suggest profit‑taking or rotation away from a stock that recently traded near its 1‑year high; that technical flow can drive near‑term downside even with favorable analyst commentary.

About AnaptysBio

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.